Cobalt Complex Catalyst for Selective Hydrogenation and Tau Aggregation Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current catalytic hydrogenation methods for unsaturated compounds face challenges in achieving selective hydrogenation of alkenes or alkynes under mild conditions without using bases or additives, and there is a need for effective inhibitors of Tau aggregation in Alzheimer's disease.
Innovation Solution
Development of a cobalt complex compound for selective hydrogenation of alkenes or alkynes at ambient temperature and neutral conditions without phosphine or additives, and its use in a pharmaceutical composition to inhibit Tau aggregation in Alzheimer's disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If base-free catalytic hydrogenation is used, then functional group compatibility is improved, but catalytic activity and selectivity deteriorate
Solution Approach 1:
The patent changes the chemical parameters of the catalyst system by using cobalt complexes with specific N-donor ligands (pyridine, imidazole, triazole, or their combinations) instead of traditional base-promoted systems. This parameter change enables the catalyst to function effectively without bases, maintaining high catalytic activity while achieving broad functional group compatibility.
Solution Approach 2:
The patent employs composite catalyst systems formed by combining cobalt salts with multiple types of N-donor ligands. These composite cobalt complex compounds create a synergistic effect where the ligand combination enhances both catalytic activity and functional group tolerance, resolving the contradiction between productivity and adaptability.
2Manufacturing precision
If mild conditions are used for semi-hydrogenation, then selectivity is improved, but reaction rate deteriorates
Solution Approach 1:
The patent optimizes reaction parameters including temperature (room temperature to 60°C), pressure (1-50 bar H2), and catalyst loading (0.1-10 mol%) to achieve high selectivity for semi-hydrogenation. The specific ligand-to-cobalt ratio and solvent selection further tune these parameters to maintain fast reaction rates under mild conditions.
Solution Approach 2:
The patent replaces harsh mechanical conditions (high temperature, high pressure, strong bases) with a finely tuned cobalt complex catalyst system that operates under mild conditions. The catalytic mechanism substitution enables selective semi-hydrogenation without requiring extreme conditions, thus maintaining both selectivity and reaction rate.
3Adaptability or versatility
If phosphine-free catalysts are used, then functional group compatibility is improved, but catalytic performance deteriorates
Solution Approach 1:
The patent substitutes phosphine ligands with N-donor ligands (pyridine, imidazole, triazole), fundamentally changing the ligand class parameter. This substitution maintains catalytic performance through optimized ligand design and cobalt complex formation while achieving superior functional group compatibility due to the softer coordination chemistry of N-donors.
Solution Approach 2:
The patent introduces local quality variations in the ligand structure through different N-donor atoms and their arrangements. This local structural optimization allows the catalyst to maintain high performance for specific transformations while being universally compatible with diverse functional groups, resolving the contradiction between reliability and adaptability.
4Adaptability or versatility
If neutral conditions without additives are used, then functional group compatibility is improved, but reaction efficiency deteriorates
Solution Approach 1:
The cobalt complex catalyst is designed to be self-sufficient, performing both catalysis and substrate activation without external additives. The N-donor ligands on the cobalt center provide the necessary electronic and steric properties to facilitate hydrogenation under neutral conditions, eliminating the need for base additives while maintaining high reaction efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cobalt complex catalyst enables efficient selective hydrogenation and effectively inhibits Tau aggregation, providing a novel approach for both chemical synthesis and therapeutic applications.
Implementation Method 1
a process for the selective hydrogenation of alkenes or alkynes in the presence of the cobalt complex compound as catalyst
Implementation Method 2
the cobalt complex compound for use in a method for inhibition of Tau Aggregation in an Alzheimer's disease
Data Source
Figure 1A~2D
Figure 3A~4
Figure 5~7C
AI summary
The present invention discloses a cobalt compound of formula (I), a process for the preparation and use thereof. The present invention further relates to a pharmaceutical composition and a method inhibition of Tau Aggregation in a subject in need thereof using compound of formula (I).